Abstract
Purpose: Data from two randomized trials, evaluating a single-day regimen of palonosetron plus dexamethasone against emesis due to moderately emetogenic chemotherapy, were assessed for the impact of age on outcome in a pooled sample of women receiving anthracycline and/or cyclophosphamide (AC)-containing chemotherapy. Methods: Chemo-naïve breast cancer patients randomized to receive palonosetron (0.25 mg) plus dexamethasone (8 mg IV) on day 1 of chemotherapy (n = 200), or the same regimen followed by oral dexamethasone (8 mg) on days 2 and 3 (n = 205), were included in the analysis. The primary endpoint was complete response (CR: no vomiting and no rescue anti-emetics) in the 5-day study period. The effect of the 1-day regimen and age (
Original language | English |
---|---|
Pages (from-to) | 565-573 |
Number of pages | 9 |
Journal | Supportive Care in Cancer |
Volume | 21 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2013 |
Keywords
- AC-containing chemotherapy
- Breast cancer
- CINV
- Dexamethasone
- Meta-analysis
- Palonosetron
ASJC Scopus subject areas
- Oncology